TMC Life Sciences Berhad (TMCLS) is set for growth in FY2026, following a resilient FY2025, driven by strategic partnerships and a focus on value-based care. At the company’s 23rd Annual General Meeting, Chairman Mohd Mokhtar bin Mohd Shariff highlighted TMCLS’s stable revenue of $73.5m (RM345.5m), a slight 0.3% decrease from FY2024, despite challenges from private insurers and corporate payors.
The group’s strategy includes enhancing community-centric services, clinical excellence, and medical tourism. A proposed single-tier final dividend of 0.1863 sen per share underscores TMCLS’s commitment to shareholder value. Thomson Hospital Kota Damansara (THKD) has partnered with OncoCare Medical Malaysia, creating a state-of-the-art cancer care facility, whilst Thomson Fertility has launched EndoCare-Thomson, focusing on endometriosis care.
Additionally, Thomson Fertility achieved Malaysia’s first live birth using the Optimal Receptivity Assay and Platelet-Rich Plasma therapy, marking a significant milestone in reproductive medicine. Looking forward, TMCLS plans to expand with the construction of Thomson Hospital Iskandariah in Johor, set to begin in H1 2026, to meet the region’s growing healthcare demands.
Group CEO Adzuan Rahman stated, “Our expansion into Johor with Thomson Hospital Iskandariah represents more than physical growth; it reflects our vision to deliver world-class value-based care closer to communities.” TMCLS aims to strengthen its position as a leading healthcare provider through strategic partnerships and clinical excellence.
